Fundamental and Clinical Studies of Ceftizoxime Suppository in the Pediatric Field

The fundamental and clinical studies of ceftizoxime suppository (CZX-S) in the field of pediatrics were made, with the following results. L The serum concentration of CZX in the CZX-S 250 mg-administered group peaked 6.00~22.5µg/ml during the period of 15 minutes to 1-hour after dosing, and gradually declined thereafter. The half-life was 1.37~3.81 hours. In the CZX-S 125 mg-administered group, the serum concentration peaked 2.25~21.0 jug/ml at 15~30 minutes after dosing and decreased with time. The half-life was 0.95~1.84 hours. 2. The 6-hour urinary recovery rate of CZX in the CZX-S 250 mg group was 22.0~47.5%. The 6-hour urinary recovery rate in the CZX-S 125 mg group was 17.2~25.3%. 3. CZX-S was given 12~73 mg/kg/day (devided into 1~3 times) to 7 children with respiratory tract infection etc. who were considered to respond well to the drug. The clinical effectiveness rate was 100% inclusive of “excellent” and “good”. 4. The side effect of pain on insertion was encountered in 1 child.